ロード中...
Evaluation of intravenous voriconazole in patients with compromised renal function
BACKGROUND: Incorporation of the solubilizing excipient, sulfobutylether-β-cyclodextrin (SBECD), in the intravenous (IV) formulation of voriconazole has resulted in the recommendation that this formulation be used with caution in patients with creatinine clearances (Cl(cr)) < 50 mL/min. This stud...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3584958/ https://ncbi.nlm.nih.gov/pubmed/23320795 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-13-14 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|